HC Wainwright & Co. Maintains Buy on Orchestra BioMed Hldgs, Raises Price Target to $12
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $10 to $12.
HC Wainwright & Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $10 to $12.